Mutations in plasticity-related-gene-1 (PRG-1) protein contribute to hippocampal seizure susceptibility and modify epileptic phenotype.


Journal

Cerebral cortex (New York, N.Y. : 1991)
ISSN: 1460-2199
Titre abrégé: Cereb Cortex
Pays: United States
ID NLM: 9110718

Informations de publication

Date de publication:
08 06 2023
Historique:
received: 01 11 2022
revised: 04 02 2023
accepted: 05 02 2023
medline: 16 6 2023
pubmed: 29 3 2023
entrez: 28 3 2023
Statut: ppublish

Résumé

The Phospholipid Phosphatase Related 4 gene (PLPPR4,  *607813) encodes the Plasticity-Related-Gene-1 (PRG-1) protein. This cerebral synaptic transmembrane-protein modulates cortical excitatory transmission on glutamatergic neurons. In mice, homozygous Prg-1 deficiency causes juvenile epilepsy. Its epileptogenic potential in humans was unknown. Thus, we screened 18 patients with infantile epileptic spasms syndrome (IESS) and 98 patients with benign familial neonatal/infantile seizures (BFNS/BFIS) for the presence of PLPPR4 variants. A girl with IESS had inherited a PLPPR4-mutation (c.896C > G, NM_014839; p.T299S) from her father and an SCN1A-mutation from her mother (c.1622A > G, NM_006920; p.N541S). The PLPPR4-mutation was located in the third extracellular lysophosphatidic acid-interacting domain and in-utero electroporation (IUE) of the Prg-1p.T300S construct into neurons of Prg-1 knockout embryos demonstrated its inability to rescue the electrophysiological knockout phenotype. Electrophysiology on the recombinant SCN1Ap.N541S channel revealed partial loss-of-function. Another PLPPR4 variant (c.1034C > G, NM_014839; p.R345T) that was shown to result in a loss-of-function aggravated a BFNS/BFIS phenotype and also failed to suppress glutamatergic neurotransmission after IUE. The aggravating effect of Plppr4-haploinsufficiency on epileptogenesis was further verified using the kainate-model of epilepsy: double heterozygous Plppr4-/+|Scn1awt|p.R1648H mice exhibited higher seizure susceptibility than either wild-type, Plppr4-/+, or Scn1awt|p.R1648H littermates. Our study shows that a heterozygous PLPPR4 loss-of-function mutation may have a modifying effect on BFNS/BFIS and on SCN1A-related epilepsy in mice and humans.

Identifiants

pubmed: 36977636
pii: 7091604
doi: 10.1093/cercor/bhad051
doi:

Substances chimiques

NAV1.1 Voltage-Gated Sodium Channel 0
Prg-1 protein, mouse 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

7454-7467

Informations de copyright

© The Author(s) 2023. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Auteurs

Ellen Knierim (E)

Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität Berlin, and Berlin Institute of Health, NeuroCure Clinical Research Center, 10117 Berlin, Germany.
Department of Neuropediatrics, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität Berlin, and Berlin Institute of Health, 10117 Berlin, Germany.

Johannes Vogt (J)

Department of Molecular and Translational Neuroscience, Institute of Anatomy II, Cluster of Excellence-Cellular Stress Response in Aging-Associated Diseases (CECAD), Center of Molecular Medicine Cologne (CMMC), University of Cologne, 50931 Cologne, Germany.

Michael Kintscher (M)

Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität Berlin, and Berlin Institute of Health, Neuroscience Research Center, 10117 Berlin, Germany.
Department of Neurology and Epileptology, Hertie Institute for Clinical Brain Research, 72076 Tübingen, Germany.

Alexey Ponomarenko (A)

Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität Berlin, and Berlin Institute of Health, Neuroscience Research Center, 10117 Berlin, Germany.
Leibniz-Institut für Molekulare Pharmakologie, 13125 Berlin, Germany.

Jan Baumgart (J)

Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität Berlin, and Berlin Institute of Health, Institute of Neurophysiology, 10117 Berlin, Germany.
Translational Animal Research Center (TARC), University Medical Center Mainz, 55128 Mainz, Germany.

Prateep Beed (P)

Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität Berlin, and Berlin Institute of Health, Neuroscience Research Center, 10117 Berlin, Germany.

Tatiana Korotkova (T)

Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität Berlin, and Berlin Institute of Health, Neuroscience Research Center, 10117 Berlin, Germany.
Leibniz-Institut für Molekulare Pharmakologie, 13125 Berlin, Germany.

Thorsten Trimbuch (T)

Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität Berlin, and Berlin Institute of Health, Institute of Neurophysiology, 10117 Berlin, Germany.

Axel Panzer (A)

Pediatric Neurology, DRK Kliniken-Westend, 14050 Berlin, Germany.

Ortrud K Steinlein (OK)

Institute of Human Genetics, Ludwig-Maximilians-University of Munich, 80336 Munich, Germany.

Ulrich Stephani (U)

Department of Child and Adolescent Medicine II, University Medical Center of Schleswig-Holstein, Campus Kiel, 24105 Kiel, Germany.

Andrew Escayg (A)

Department of Human Genetics, Emory University, Atlanta, GA 30322, United States.

Mahmoud Koko (M)

Department of Neurology and Epileptology, Hertie Institute for Clinical Brain Research, 72076 Tübingen, Germany.

Yuanyuan Liu (Y)

Department of Neurology and Epileptology, Hertie Institute for Clinical Brain Research, 72076 Tübingen, Germany.

Holger Lerche (H)

Department of Neurology and Epileptology, Hertie Institute for Clinical Brain Research, 72076 Tübingen, Germany.

Dietmar Schmitz (D)

Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität Berlin, and Berlin Institute of Health, NeuroCure Clinical Research Center, 10117 Berlin, Germany.
Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität Berlin, and Berlin Institute of Health, Neuroscience Research Center, 10117 Berlin, Germany.
Humboldt-Universität zu Berlin, Bernstein Center for Computational Neuroscience, 10115 Berlin, Germany.
Max Delbrück Center for Molecular Medicine in the Helmholtz Association, 13125 Berlin, Germany.
German Center for Neurodegenerative Diseases (DZNE) Berlin, 10117 Berlin, Germany.
Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität Berlin, and Berlin Institute of Health, Einstein Center for Neuroscience, 10117 Berlin, Germany.

Robert Nitsch (R)

Institute for Translational Neuroscience, Westfälische Wilhelms University, 48149 Münster, Germany.

Markus Schuelke (M)

Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität Berlin, and Berlin Institute of Health, NeuroCure Clinical Research Center, 10117 Berlin, Germany.
Department of Neuropediatrics, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität Berlin, and Berlin Institute of Health, 10117 Berlin, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH